Giulia Papini
Siena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus.
Journal: Clinical and experimental medicine
Published: December 18, 2025
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
Journal: British journal of haematology
Published: March 13, 2016
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Journal: Anti-cancer agents in medicinal chemistry
Published: December 23, 2015
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Journal: Anti-cancer agents in medicinal chemistry
Published: August 28, 2015
Evolving treatments in multiple myeloma patients with renal failure.
Journal: Reviews on recent clinical trials
Published: July 30, 2014
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Journal: Leukemia research
Published: February 05, 2014
Single Agent Lenalidomide Activity in Multiple Myeloma Relapse Evidenced Uniquely by CT/PET.
Journal: Mediterranean journal of hematology and infectious diseases
Published: April 15, 2012
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Journal: British journal of haematology
Published: February 03, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026